Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.

MLA

Inzaule, Seth C., et al. “Clinically Relevant Thresholds for Ultrasensitive HIV Drug Resistance Testing: A Multi-Country Nested Case-Control Study.” The Lancet. HIV, vol. 5, no. 11, Nov. 2018, pp. e638–46. EBSCOhost, https://doi.org/10.1016/S2352-3018(18)30177-2.

APA

Inzaule, S. C., Hamers, R. L., Noguera-Julian, M., Casadellà, M., Parera, M., Kityo, C., Steegen, K., Naniche, D., Clotet, B., Rinke de Wit, T. F., & Paredes, R. (2018). Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. The Lancet. HIV, 5(11), e638–e646. https://doi.org/10.1016/S2352-3018(18)30177-2

Chicago

Inzaule, Seth C, Raph L Hamers, Marc Noguera-Julian, Maria Casadellà, Mariona Parera, Cissy Kityo, Kim Steegen, et al. 2018. “Clinically Relevant Thresholds for Ultrasensitive HIV Drug Resistance Testing: A Multi-Country Nested Case-Control Study.” The Lancet. HIV 5 (11): e638–46. doi:10.1016/S2352-3018(18)30177-2.